Terns Pharmaceuticals (TERN) last traded on May 4, 2026. A Form 15-12G filed on May 15, 2026 ends the SEC registration of its shares.
What Changed
Price Move History
- Daily moves over 5%
- 55 252 sessions, May 2, 2025 to May 4, 2026
- Largest daily move
- +69.9% close of November 3, 2025
- 1-year change
- +1412.9% closing prices, May 2, 2025 to May 4, 2026
- 1-month change
- +0.4% closing prices, April 2, 2026 to May 4, 2026
Company Description
Written before these shares stopped trading.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company that focuses on developing medicines based on known biology. The company describes its approach as "reimagining known biology to deliver high impact medicines," with an emphasis on cancer indications. Terns is listed on the Nasdaq Global Select Market under the trading symbol TERN and is associated in SEC filings with Foster City, California.
The centerpiece of Terns Pharmaceuticals’ pipeline is TERN-701, which the company repeatedly identifies as its lead program. TERN-701 is described as a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor. It is being developed for patients with chronic myeloid leukemia (CML), including those with previously treated or relapsed/refractory disease. Company materials characterize TERN-701 as an investigational therapy that could meaningfully improve upon the efficacy, safety and convenience of existing CML treatments.
Core focus and clinical development
Terns states that it has completed a transition to an oncology-focused company anchored by TERN-701 for CML. The drug is being evaluated in the CARDINAL trial (NCT06163430), a global, multicenter Phase 1/2 clinical study. According to company disclosures and related SEC filings, CARDINAL includes a dose escalation phase and a dose expansion phase designed to assess safety, tolerability and efficacy in patients with previously treated chronic phase CML.
The dose escalation portion of CARDINAL was completed with no dose-limiting toxicities observed up to a maximum dose of 500 mg once daily. Terns reports that the dose expansion portion randomizes patients to two dose cohorts, 320 mg or 500 mg once daily, with up to 40 patients per arm. Across company press releases and the related Form 8-K, Terns highlights data such as major molecular response (MMR) rates by 24 weeks, deep molecular response (DMR) rates, and safety findings, particularly in heavily pretreated and difficult-to-treat CML populations.
Therapeutic area and scientific approach
In its public communications, Terns consistently describes itself as a clinical-stage oncology company. The company’s stated goal is to deliver high impact medicines by reimagining known biological mechanisms. For TERN-701, this centers on allosteric inhibition of BCR-ABL in CML. Company materials emphasize oral administration, selectivity, and the potential to address patients who have received multiple prior tyrosine kinase inhibitors (TKIs), including asciminib, ponatinib and other marketed or investigational TKIs.
The CARDINAL trial data summarized in company news and SEC filings describe patient populations with multiple prior TKIs, baseline BCR::ABL1 transcript levels above 1% or 10%, and the presence of BCR::ABL1 mutations. Terns highlights overall and subgroup MMR rates, the maintenance of MMR, and the proportion of low-grade treatment-emergent adverse events, as part of its characterization of TERN-701’s clinical profile.
Pipeline and legacy programs
In addition to TERN-701, Terns has disclosed other programs and assets. The company refers to discovery efforts on undisclosed targets for oncology indications, indicating ongoing early-stage research in cancer beyond CML. Terns also references legacy metabolic programs and states that it is seeking strategic partners to advance them.
These legacy programs include TERN-501, described as an oral thyroid hormone receptor-beta (THR-β) agonist, and TERN-801, described as an oral small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist that was nominated as a development candidate from the TERN-800 series discovery effort. The company notes that it decided to discontinue internal clinical development of its metabolic programs and is looking to external partnerships to realize their potential.
Another disclosed program is TERN-601, an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) that was evaluated in a Phase 2 study for obesity. Terns reports that top-line 12-week data showed a certain level of placebo-adjusted weight loss and treatment discontinuation due to adverse events, including asymptomatic, reversible grade 3 liver enzyme elevations in some participants. The company states that these results did not support further internal development of TERN-601 in obesity and reiterates its decision to no longer invest in metabolic disease internally.
Capital markets activity and financial reporting
Terns Pharmaceuticals is an SEC-reporting company and files periodic and current reports, including Form 8-K filings that reference quarterly financial results and clinical updates. The company has conducted underwritten public offerings of common stock, with press releases and related registration statements on Form S-3 describing offerings of shares of common stock and, in some cases, pre-funded warrants. These offerings are described as intended to fund research, clinical trials, development and manufacturing of key product candidates, including TERN-701, as well as initial activities related to potential future commercial launch of TERN-701, working capital and general corporate purposes.
In its financial communications, Terns reports operating expenses such as research and development and general and administrative costs, as well as cash, cash equivalents and marketable securities. The company also provides guidance on expected cash runway based on its operating plan. These details appear in press releases that are furnished or incorporated by reference in Form 8-K filings.
Regulatory and clinical milestones
Company news indicates that TERN-701 received U.S. FDA Fast Track designation for the treatment of CML. Terns also outlines anticipated milestones for TERN-701, including dose selection for pivotal studies, regulatory interactions such as an end-of-Phase 2 meeting with the U.S. Food and Drug Administration, updates to CARDINAL trial data, and plans for initiating pivotal trials in certain CML treatment lines. These milestones are described in company press releases as expectations and goals and are accompanied by cautionary notes regarding forward-looking statements.
Terns frequently highlights scientific and clinical presentations related to TERN-701, including oral presentations at major hematology conferences such as the American Society of Hematology (ASH) Annual Meeting. The company’s disclosures summarize efficacy and safety data from the CARDINAL trial, including MMR and DMR rates, safety profiles, and outcomes in subgroups with prior exposure to other TKIs.
Position within the biopharmaceutical landscape
According to company descriptions and SEC filings, Terns Pharmaceuticals operates as a clinical-stage biopharmaceutical organization with a primary focus on oncology, particularly CML. Its activities center on the clinical development of TERN-701, the management of legacy metabolic assets for potential partnering, and ongoing discovery work on additional oncology targets. Public statements emphasize the potential for TERN-701 to address unmet needs in CML, especially in patients who have received multiple prior therapies.
Investors and observers can follow Terns’ progress through its Nasdaq listing under the symbol TERN, its periodic SEC filings, and its press releases detailing clinical data, financial results, capital raises and corporate updates.
Stock Performance
Terns Pharmaceuticals (TERN) closed at $52.95 on May 4, 2026. In the 12 months to May 4, 2026, the price gained 1412.9%.
TERN Metrics & Rankings
Price returns through May 4, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Terns Pharmaceuticals has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition. View all TERN news →
SEC Filings
Terns Pharmaceuticals has filed 10 recent SEC filings, including 5 Form 4, 3 Form SCHEDULE 13G/A, 1 Form 15-12G, 1 Form EFFECT. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TERN SEC filings →
Financial Highlights
Terns Pharmaceuticals reported operating income of -$110.1M in FY2025, and net income was -$96.2M. Diluted earnings per share stood at -$1.03. The company generated -$82.2M in operating cash flow. The current ratio was 62.41, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Terns Pharmaceuticals (TERN) currently stands at 5.5 million shares, down 31.3% from the previous reporting period, representing 4.9% of the float. Since November 2025, short interest has decreased by 37.0%.
Days to Cover History
Days to cover for Terns Pharmaceuticals (TERN) currently stands at 1.5 days, up 46% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 37.3%. Across the settlements charted above, it has ranged from 1.0 to 9.6 days.
TERN Company Profile & Sector Positioning
Terns Pharmaceuticals (TERN) operates in the Biotechnology industry within the broader Healthcare sector.
Investors comparing TERN often look at related companies in the same sector, including Enliven Therapeutics, Inc. (ELVN), PMV Pharmaceuticals, Inc (PMVP), Biomea Fusion, Inc. (BMEA), Viking Therapeutics, Inc (VKTX), and Oric Pharmaceuticals, Inc. (ORIC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TERN's relative position within its industry.